NasdaqCM:BLFSLife Sciences
How BioLife’s Exclusive Qkine Cytokine Deal Could Rewire the BLFS Cell and Gene Therapy Story
On 12 February 2026, BioLife Solutions, Inc. announced a multi-year agreement to distribute Qkine Limited’s cytokine and growth factor products globally for cell and gene therapy manufacturing, with plans to integrate select products into BioLife’s CellSeal® Connect vial system.
This deal broadens BioLife’s reach into the US$500 million cytokines market, which third-party research suggests could reach about US$1.00 billion by 2030, directly linking its biopreservation tools with critical CGT...